MorphoSys AG operates as a commercial-stage biopharmaceutical firm, concentrating on the discovery, development, and marketing of therapeutic antibodies. Its primary focus is on addressing cancer and autoimmune conditions, particularly within the United States. The company's lead commercial product is Tafasitamab, an antibody used to treat various B-cell cancers, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. MorphoSys's development pipeline includes several promising candidates: Pelabresib, a small molecule, is currently in Phase II trials for myelofibrosis. Felzartamab, an antibody targeting CD38, is undergoing Phase I/II clinical evaluation for anti-PLA2R-positive membranous nephropathy, an autoimmune disorder. Another small molecule, CPI-0209, is in Phase I/II studies, engineered to boost anti-tumor effects by inhibiting EZH2. Through collaborations with pharmaceutical partners, MorphoSys also contributes to the development of other antibody treatments, such as: Gantenerumab for Alzheimer's disease. Otilimab for rheumatoid arthritis. Tremfya, addressing psoriasis, psoriatic arthritis, and palmoplantar pustulosis. MOR210/TJ210 for immuno-oncology and autoimmune conditions. The company maintains a variety of strategic alliances and agreements. These include a regional licensing deal with I-Mab Biopharma for the development and commercialization of felzartamab across China, Taiwan, Hong Kong, and Macau. MorphoSys has a strategic alliance with LEO Pharma and a joint collaboration and licensing agreement with Incyte Corporation for the development and commercialization of its investigational compound, tafasitamab. Furthermore, a clinical collaboration exists with Incyte Corporation and Xencor, Inc. to investigate a combination of tafasitamab, plamotamab, and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma and relapsed or refractory follicular lymphoma. Established in 1992, MorphoSys AG is headquartered in Planegg, Germany.